Floatz Rating
C38/100
Confidence
Indicative
Sponsor
Nationwide Children's Hospital
Modality
Small molecule
Development Phase
Early Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
24Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06333899CT.gov Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Malignant Glioma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Lorlatinib (this asset) | Nationwide Children's Hospital | Early P1 | C · 38 |
| Irinotecan | Kailin Yang, MD, PhD | P2 | BB |
| Marizomib | Aadi Bioscience, Inc. | P2 | BB |
| Valaciclovir | Trogenix ltd | P2 | BB |
| Disodium 4-((Tert-Butylimino)Methyl)Benzene-1,3-Disulfonate N-Oxide | Oblato, Inc. | P2 | BB |
| Nogitecan | Jeffrey N. Bruce | P2 | B |
| Lenalidomide | M.D. Anderson Cancer Center | P2 | B |
| Gm-Csf | Gary Archer Ph.D. | P2 | B |
| Nivolumab | University of Florida | P2 | B |
+42 more in the Malignant Glioma cohort
Other indications for Lorlatinib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Non-Small Cell Lung Carcinoma | — | P4 | BB · 66 |
| Hepatocellular Carcinoma | — | P4 | BB · 64 |
| Neoplastic Meningitis | — | P4 | B · 62 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Lorlatinib in Malignant Glioma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/lorlatinib-malignant-glioma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →